[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100497929":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":18,"locations":25,"responsibleParty":56,"collaborators":7,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":7,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":7,"enrollmentInfo":68,"targetDuration":71,"studyType":72,"phases":7,"briefSummary":73,"conditions":74,"keywords":7,"overallStatus":28,"whyStopped":7,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Hospital Universitari de Bellvitge","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"PROCEDURE","Target Axillary Dissection","TAD after neoadjuvant chemotherapy and subsequent axillary lymph node dissection",[14],{"name":15,"affiliation":16,"role":17},"amparo Garcia-Tejedor, MDPhD","Instituto de Investigación Biomédica de Bellvitge (IDIBELL)","PRINCIPAL_INVESTIGATOR",[19],{"name":20,"role":21,"phone":22,"phoneExt":23,"email":24},"Amparo García-Tejedor, MDPhD","CONTACT","0034-932607702","2812","agarciat@bellvitgehospital.cat",[26,44],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Hospital de Bellvitge","RECRUITING","L'Hospitalet de Llobregat","Barcelona","08907","Spain","ES",{"type":35,"coordinates":36},"Point",[37,38],2.10028,41.35967,{"lat":38,"lon":37},[41],{"name":42,"role":21,"phone":43,"phoneExt":7,"email":24},"Amparo Garcia-Tejedor, MDPhD","0034-660223417",{"facility":45,"status":28,"city":30,"state":7,"zip":46,"country":32,"countryCode":33,"cosmosGeoPoint":47,"geoPoint":51,"contacts":52},"Hospital Clínico y Provincial de Barcelona","08036",{"type":35,"coordinates":48},[49,50],2.15899,41.38879,{"lat":50,"lon":49},[53],{"name":54,"role":21,"phone":7,"phoneExt":7,"email":55},"Isaac Cebrecos, MD","CEBRECOS@clinic.cat",{"type":17,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Amparo Garcia-Tejedor","Clinical Professor","100497929","tad-after-chemotherapy-in-locally-advanced-breast-cancer-100497929",false,"NCT05763641","TAD After Chemotherapy in Locally Advanced Breast Cancer","Target Axillary Dissection After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer","Inclusion Criteria:\n\n* Axillary lymph node metastasis proven by cytology\n* Clinical or radiological N2a (at least 4 suspicious lymph nodes on axillary ultrasound at diagnosis)\n* Extensive T4 subsidiary to axillary lymphadenectomy according to current clinical criteria\n* Neoadjuvant chemotherapy\n\nExclusion Criteria:\n\n* cN3 verified by imaging tests\n* N2 due to internal mammary involvement (N2b).\n* Tumors whose surrogate molecular subtype is luminal A.\n* Patients undergoing neoadjuvant endocrine therapy\n* Patients with local recurrences and metastatic tumors.","ALL","18 Years",{"count":69,"type":70},162,"ESTIMATED","3 Years","OBSERVATIONAL","This is an observational study to validate target axillary dissection (TAD) in locally advanced tumors (cN2 and\u002For cT4).",[75,76,77],"Sentinel Lymph Node","Breast Cancer","Locally Advanced","2025-09-08",{"date":80,"type":81},"2025-09-10","ACTUAL",{"date":83,"type":81},"2021-02-01",{"date":85,"type":70},"2026-06-01",{"name":5,"class":6},2]